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Type 2 myocardial infarction: incidence, presentation,
treatment and outcome in routine clinical practice
Dragana Radovanovica, Thomas Pilgrimb, Burkhardt Seifertc, Philip Urband,
Giovanni Pedrazzinie and Paul Ernef
Aims The clinical definition and optimal treatment for
myocardial infarction (MI) type 2 (T2MI) are not well
established. We assessed differences in presentation,
treatment and outcomes of patients with MI type 1 (T1MI)
and T2MI.
Methods The data of MI patients enrolled in the AMIS Plus
cohort with T2MI were compared with T1MI using
propensity score matching.
Results A total of 13829 patients had T1MI and 1091 (7.3%)
T2MI. Patients with T2MI were older, often female, withmore
risk factors and comorbidities, and less ST segment
elevation. After matching for these differences (1091 per
group), T2MI patients less often presented with typical
chest pain butmore frequently with atrial fibrillation (15.6 vs.
4.9%; P<0.001) and anemia (33.5 vs. 23.3%; P<0.001) than
patients with T1MI. They less frequently received
percutaneous coronary interventions (51.1 vs. 76.4%;
P<0.001) and antiplatelet treatment. No differences were
found for in-hospital (5.8 vs. 5.6%; OR 1.04; 95% confidence
interval 0.72–1.49) and 1-year mortality (11.2 vs. 7.2%;
PU0.38) between matched T2MI and T1MI patients.
Conclusion Patients who suffered a T2MI had less typical
symptoms, were less aggressively treated with
anticoagulants, platelet inhibitors or percutaneous coronary
intervention, but had similar complications and mortality to
those with T1MI. Patients with T2MI are a heterogeneous
group that requires further investigation to better define
optimal therapeutic approaches.
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Introduction
The Task Force for the universal definition of myo-
cardial infarction (MI) introduced in 2007 clinically
classified MI into five types.1 The most common form
of MI is type 1 (T1MI), which occurs in atherosclerotic
coronary arteries by plaque rupture, ulceration, erosion
or dissection with thrombotic obstruction. MI type 2
(T2MI) is an imbalance between oxygen demand and
supply in the presence or absence of atherosclerotic
coronary artery disease. This may be caused by various
conditions, such as anemia, arrhythmia, spasm, hyper-
tension or hypotension, but no specific criteria for
making a diagnosis of T2MI have been established.
Therefore, this type of MI has been the subject of
considerable clinical discussion.2–4 A large spectrum
of underlying causes for T2MI open medical manage-
ment to different treatment strategies.5,6 The aim of
this study was to assess differences in presentation
and outcome of patients with T1MI and T2MI, deter-
mined by clinicians in ‘real world situations’ by compar-
ing two main types of MI with regard to baseline
characteristics, therapies and outcomes using propensity
score matching.
Methods
The AMIS Plus project is an ongoing nationwide
prospective cohort of patients admitted with acute
coronary syndromes (ACSs) to hospitals in Switzerland.
It was founded by the Swiss Societies of Cardiology,
Internal Medicine and Intensive Care Medicine in
1997 with the goal to understand the transfer, use and
practicability of knowledge gained from randomized
trials in the real world of daily clinical practice. Details
have been previously published.7–9
Among 106 hospitals treating ACS in Switzerland, 83
hospitals temporarily or continuously enrolled patients
in AMIS Plus. Participating centers, ranging from com-
munity institutions to large tertiary facilities, provided
blinded data for each patient through standardized inter-
net-based or paper-based questionnaires. Standard pro-
cedures ensured a low percentage of missing data.
External monitoring has been regularly performed since
2010 in randomly selected hospitals and patients.
The registry was approved by the Supra-Regional Ethics
Committee for Clinical Studies, the Swiss Board for Data
Security and all Cantonal Ethics Commissions. Data
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collection is conducted in accordance with the EU Note
for Guidance on Good Clinical Practice CPMP/ECH/
135/95 and the Declaration of Helsinki.
The AMIS Plus cohort included patients admitted to a
participating hospital with one of the following final
diagnoses: ST elevation MI (STEMI), non-ST elevation
(NSTEMI) or unstable angina. Diagnoses were based on
symptoms, ECG and/or cardiac biomarkers, and
conformed to the prevailing guidelines in use at the
time of inclusion. The universal definitions of MI types
were first introduced in 2007.1 In 2008, the MI types
were added to the AMIS Plus case report form. These
were then defined according to the discretion of the
treating physician.
In this study, we analyzed the patients enrolled in AMIS
Plus from January 2009 to July 2015 with final discharge
diagnoses of either T1MI of T2MI and compared their
presentations, treatments and outcomes.
Information on known risk factors was obtained from the
patients’ medical history. Dyslipidemia, arterial hyper-
tension and diabetes were considered if the patient was
previously treated for such a condition and/or diagnosed
by a physician. Patients were defined as obese if the BMI
was at least 30 kg/m2 and as smokers if the patients
were smokers at the time of the cardiovascular event.
Patient comorbidities were assessed using the Charlson
index.10,11 Immediate drug therapy was defined if
administrated within 24 h after admission. Anemia was
defined according to WHO criteria [hemoglobin (Hb)
below 12 g/dl for women and below 13 g/dl for men] and
severe anemia (Hb below 10 g/dl for women and below
11 g/dl for men). Bleeding complications were recorded if
deemed clinically relevant by the individual physician in
charge of the patient, without the use of a classification
system when data collection started. Reinfarction was
defined as clinical signs or symptoms of ischemia with
ECG changes indicative of new ischemia (new ST
changes or new left bundle branch block) and a rerise
of biomarkers following the initial infarction. A stroke was
defined as any event due to ischemic, thrombotic or
hemorrhagic disturbances confirmed by a neurologist or
an imaging modality.
The primary outcome measure of the present analysis
was in-hospital mortality. Secondary outcome measures
were the rates of in-hospital major adverse cardiac or
cerebrovascular events defined as a composite of
mortality, reinfarction and cerebrovascular events. In a
subgroup of patients who gave their informed consent,
follow-up was performed at 1 year by means of a stan-
dardized telephone interview.
Statistical analysis
We first descriptively analyzed baseline characteristics
according to the two MI types. Results are presented as
percentages for categorical variables and analyzed using
the Pearson chi-square test or Fisher’s exact test as
appropriate. Continuous normally distributed variables
are expressed as means 1 SD and compared using the
Student’s two-tailed unpaired t test. Continuous non-
normally distributed variables are expressed as medians
and interquartile ranges and analyzed using the Mann–
Whitney U test. In case of missing data, we fused n/N
(number of patients with a characteristic/number of
patients with available data). A two-sided P value less
than 0.05 was considered statistically significant.
To correct for baseline imbalances, we analyzed a pro-
pensity matched sample from the crude population. For
the computation of the propensity score, the following
nine variables were included in a nonparsimonious logis-
tic regression with MI type as the dependent variable:
age, sex, STEMI, Killip class more than 2, resuscitation
prior to admission, history of diabetes mellitus, arterial
hypertension, coronary artery disease and Charlson
comorbidity index more than 1. Matching for the sub-
group of T2MI and T1MI patients followed 1 year after
the event was performed in proportions of 1 : 1, 1 : 5 and
1 : 10 to keep the number of matched patients with T2MI
as high as possible. Missing values were replaced by
multiple regression imputation for the respective
analysis. The validity of logistic regression was assessed
using the Hosmer–Lemeshow test. Propensity matching
was performed using the package Matching in R.12
The IBMSPSS Statistics Version 22 (IBMCorp; Armonk,
New York, USA) was used for other statistical analyses.
Results
Among 15 505 patients with documented MI types,
14 919 with either T1MI or T2MI were included from
53 Swiss hospitals (Fig. 1). Seventy-four percent were
men (aged 64.1 12.7 years) and 26% were women (aged
71.6 12.8 years). From these patients, 1091 (7.3%) were
classified as having T2MI, and the yearly rate of T2MI
patients did not significantly change during the study
period (P¼ 0.44). The most frequent clinical presenta-
tions thought to be causal to T2MI were known in 685
patients and were anemia 48.3%, atrial fibrillation 24.8%,
perioperative 7.4%, hypertonia/hypoxia 5.3%, infection
5.3%, other tachyarrhythmia 5.0%, bleeding 2.5% and
other reasons 1.5%.
Table 1 shows the baseline characteristics of patients
with T1MI and T2MI in the crude and in the matched
samples. Patients with T2MIwere older, more frequently
women; more frequently had a history of hypertension,
coronary artery disease, diabetes and comorbidities; but
they less frequently presented with STEMI or with
typical chest pain. Atrial fibrillation was present in
15.6% of patients with T2MI vs. 4.9% of T1MI patients,
and 33.5% of patients with T2MI had anemia vs. 17.3% of
patients with T1MI (P< 0.001), and both these differ-
ences persisted after matching.
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Immediate drug therapy was different between patients
with T1MI and those with T2MI. In the crude sample,
84.5% underwent percutaneous coronary intervention
(PCI) compared with 76.4% of the matched patients with
T1MI, whereas 15.5%, respectively 23.6%, were treated
conservatively. From patients with T2MI, 48.5%
received conservative treatment and 51.5% an interven-
tion (P< 0.001). From the patients with angiographic
data, no angiographic findings [excluding nonobstructive
coronary artery disease (<50% stenosis)] were documen-
ted for 47/655 (7.2%) patients with T2MI, 31/12 047
(0.3%) in unmatched and in 2/878 (0.2%) in matched
patients with T1MI (P< 0.001).
In-hospital medical treatment of patients with T1MI and
T2MI is summarized in Table 2. Although the adminis-
tration of beta blockers, angiotensin-converting enzyme
inhibitors and angiotensin II receptor antagonist
antagonists were comparable between the two groups,
patients with T2MI were less aggressively treated with
antiplatelet agents and statins.
Odds ratios of in-hospital outcomes of patients with
T1MI compared with those with T2MI are shown in
Fig. 2 (unmatched) and in Fig. 3 (matched cohort). In the
matched cohort, there were no significant differences
between patients presenting with T1MI or T2MI with
regard to the risk of cardiogenic shock, reinfarction,
cerebrovascular events, acute renal failure, bleeding or
in-hospital mortality.
Cause of death in both MI types was mainly cardiac:
3.1% in T2MI, 3.0% in T1MI unmatched and 3.5%
in matched T1MI patients (P¼ 0.87 and 0.72,
respectively).
For subgroup analysis 1 year after discharge, a total of
3375 patients were followed up (3.7% had T2MI and
95.3% had T1MI). No differences were found in rehos-
pitalization rates (24.5 vs. 24.8%; P¼ 1.00) or reinterven-
tions (14.4 vs. 16.2%; P¼ 0.70), but unadjusted mortality
was higher in patients with T2MI (11.2 vs. 3.6%;
P< 0.001). However, mortality of patients with T2MI
1 year after discharge was not significantly different
compared with T1MI patients in the 1 : 10 matched
sample (120 : 1200 patients) (9.2 vs. 6.6%; P¼ 0.30), in
the 1 : 5 matched sample (124 : 620 patients) (11.3 vs.
7.6%; P¼ 0.21) as well as in the 1 : 1 matched sample
(125 : 125 patients) (11.2 vs. 7.2%; P¼ 0.38). Among
patients with known cause of death after 1 year, 38%
of T2MI patients died of noncardiac causes vs. 17% of
T1MI patients.
Discussion
The current study documents significant differences
between patients classified as having T2MI or T1MI
in current everyday practice. Patients with T2MI more
frequently had atrial fibrillation, anemia, NSTEMI and
fewer treatable stenoses. However, the practical impact
of distinguishing between MI types 1 and 2 does not
seem to be clearly established in routine care.
In a Danish study, the frequency of T2MI was 26%, in
which features of this type of MI were investigated using
novel developed criteria in consecutive patients admitted
to one university hospital during 1 year13 and was there-
fore much higher than in our cohort (7%). It is possible
that T2MI was overlooked in our population or not even
included in the cohort due to minimal elevation of
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Fig. 1
Type 1
N = 13 828
(89.2%)
Type 2
N = 1091
(7.0%)
Type 3
N = 40
(0.3%)
Type 4
N = 482
(3.1%)
Type 5
N = 64
(0.4%)
Type 4a
N = 52
(0.3%)
Type 4b
N = 430
(2.8%)
My type not
recorded
N = 1208 (7.2%)
AMIS Plus
2009–2015
N = 16 713
My type recorded
N = 15 505
Clinical classification of different types of myocardial infarction in AMIS Plus 2009–2015.
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biomarkers or a nonspecific ECG together with an
absence of typical chest pain, which could be considered
as not fulfilling the AMIS Plus inclusion criteria. The
reported incidence of T2MI in the literature varies
widely (1.6–26%), reflecting the lack of well defined
diagnostic criteria.6,14
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Table 1 Baseline characteristics of AMI patients according to myocardial infarction types 1 or 2 (nU14919)
Unmatched Matcheda
MI type 1 MI type 2
P
MI type 1 MI type 2
PNumber of patients 13 828 1091 1091 1091
Sex female (%) 3517/13 828 (25.4) 387/1091 (35.5) <0.001 389/1091 (35.7) 387/1091 (35.5) 0.96
Age in years, mean (SD) 65.7 (13.1) 70.8 (13.3) <0.001 70.6 (12.3) 70.8 (13.3) 0.78
ST segment elevation (%) 7436/13 828 (53.8) 213/1091 (19.5) <0.001 216/1091 (19.8) 213/1091 (19.5) 0.91
Resuscitation prior admission (%) 811/13 826 (5.9) 40/1091 (3.7) 0.002 39/1090 (3.6) 40/1091 (3.7) 1.00
Killip classes 3/4 (%) 1016/13 783 (7.4) 83/1086 (7.6) 0.72 86/1088 (7.9) 83/1086 (7.6) 0.87
History of hypertension (%) 8009/13 016 (61.5) 766/1042 (73.5) <0.001 779/1053 (74.0) 766/1042 (73.5) 0.84
Coronary artery disease (%) 3685/13 369 (27.6) 392/1066 (36.8) <0.001 394/1054 (37.4) 392/1066 (36.8) 0.79
Diabetes (%) 2626/13 137 (20.0) 276/1055 (26.2) <0.001 312/1047 (29.8) 276/1055 (26.2) 0.065
Charlson Index >1(%)b 2875/13 828 (20.8) 400/1091 (36.7) <0.001 416/1091 (38.1) 400/1091 (36.7) 0.51
Symptoms at admission
Pain (%) 12 406/13 356 (92.9) 809/1035 (78.2) <0.001 936/1053 (88.9) 809/1035 (78.2) <0.001
Dyspnea (%) 3916/12 018 (32.6) 428/969 (44.2) <0.001 372/960 (38.8) 428/969 (44.2) 0.016
Vital signs at admission mean (SD)
SBP (mmHg) 137 (29) 136 (29) 0.37 141 (28) 136 (29) <0.001
DBP (mmHg) 80 (17) 77 (17) <0.001 79 (17) 77 (18) 0.003
Heart rate (beats/min) 78 (19) 84 (25) <0.001 79 (19) 84 (25) <0.001
Heart rhythm
Sinus rhythm (%) 12 629/13 826 (91.3) 857/1091 (78.6) <0.001 991/1091 (90.8) 857/1091 (78.6) <0.001
Atrial fibrillation (%) 566/13 826 (4.1) 170/1091 (15.6) <0.001 53/1091 (4.9) 170/1091 (15.6) <0.001
Risk factors
Family history (%) 3699/11 215 (33.0) 243/824 (29.5) 0.042 274/856 (32.0) 243/824 (29.5) 0.27
Smoking (%) 4978/12 086 (41.2) 282/904 (31.2) <0.001 296/926 (32.0) 282/904 (31.2) 0.73
Dyslipidemia (%) 7104/12 157 (58.4) 565/977 (57.8) 0.71 625/979 (63.8) 565/977 (57.8) 0.007
Obesity (BMI>30) (%)c 2718/12 173 (22.3) 213/944 (22.6) 0.87 240/945 (25.4) 213/944 (22.6) 0.16
Anemia (%) 2234/12 890 (17.3) 331/987 (33.5) <0.001 238/1021 (23.3) 331/987 (33.5) <0.001
Severe anemia (%) 530/12 890 (4.1) 146/987 (14.8) <0.001 57/1021 (5.6) 146/987 (14.8) <0.001
Comorbidities
Heart failure (%) 288/13 441 (2.1) 73/1074 (6.8) <0.001 51/1066 (4.8) 73/1074 (6.8) 0.052
Cerebrovascular disease (%) 746/13 441 (5.6) 83/1074 (7.7) 0.004 113/1066 (10.6) 83/1074 (7.7) 0.024
Peripheral arterial disease (%) 634/13 441 (4.7) 101/1074 (9.4) <0.001 80/1056 (7.5) 101/1074 (9.4) 0.12
Moderate-to-severe renal disease (%) 953/13 442 (7.1) 156/1074 (14.5) <0.001 139/1066 (13.0) 156/1074 (14.5) 0.35
Cancer disease (%) 759/13 441 (5.6) 93/1074 (8.7) <0.001 82/1066 (7.7) 93/1074 (8.7) 0.43
Dementia (%) 212/13 441 (1.6) 37/1074 (3.4) <0.01 29/1066 (2.7) 37/1074 (3.4) 0.38
In case of missing data, N¼ number of patients with available data and n/N¼ number of patients with a characteristic/number of patients with available data. a Matched for
age, gender, ST elevation, resuscitation prior admission, Killip class more than 2, history of hypertension, coronary artery disease, diabetes and Charlson comorbidity index
more than 1. b Charlson Comorbidity Index.
Table 2 Immediate therapy of AMI patients according to myocardial infarction types 1 or 2 (nU14919)
Unmatched Matched
MI type 1 MI type 2
P MI type 1 MI type 2 PNumber of patients 13 828 1091
Medicaments
Aspirin (%) 13 270/13 772 (96.4) 983/1084 (90.7) <0.001 1034/1089 (94.9) 983/1084 (90.7) <0.001
P2Y12 inhibitors (%) 12 488/13 769 (90.7) 786/1082 (72.6) <0.001 944/1087 (86.8) 786/1082 (72.6) <0.001
GP IIb/IIIa antagonist (%) 2176/13 518 (16.1) 34/1059 (3.2) <0.001 92/1064 (8.6) 34/1059 (3.2) <0.001
Heparin (%) 11 774/13 703 (85.9) 801/1082 (74.0) <0.001 882/1079 (81.7) 801/1082 (74.0) <0.001
Beta-blocker (%) 7396/13 655 (54.2) 595/1074 (55.4) 0.45 604/1075 (56.2) 595/1074 (55.4) 0.73
ACEI/ARB antagonist (%) 7448/13 665 (54.5) 566/1081 (52.4) 0.17 574/1080 (53.1) 566/1081 (52.4) 0.73
Ca-channel blocker (%) 1244/13 490 (9.2) 161/1066 (15.1) <0.001 144/1068 (13.5) 161/1066 (15.1) 0.29
Nitrate (%) 6191/13 542 (45.7) 425/1070 (39.7) <0.001 493/1063 (46.4) 425/1070 (39.7) 0.002
Diuretic (%) 2648/13 532 (19.6) 373/1073 (34.8) <0.001 308/1066 (28.9) 373/1073 (34.8) 0.004
Statin (%) 10 555/13 689 (77.1) 698/1077 (64.8) <0.001 819/1082 (75.7) 698/1077 (64.8) <0.001
Intervention
Coronary angiography (%) 12 067/13 828 (87.3%) 660/1091 (60.5%) <0.001 880/1091 (80.7) 660/1091 (60.5) <0.001
PCI (%) 11 684/13 828 (84.5) 557/1091 (51.1) <0.001 833/1091 (76.4) 557/1091 (51.1) <0.001
In case of missing data, N¼ number of patients with available data and n/N¼ number of patients with a characteristic/number of patients with available data. ACEI,
angiotensin-converting enzyme inhibitor; ARB, angiotension II receptor antagonist; P2Y12 inhibitors, clopidogrel, prasugrel or ticagrelor; PCI, percutaneous coronary
intervention.
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The question is how to deal with the classification of
T2MI in a real-world situation when there is a lack of
internationally accepted criteria for diagnosing T2MI.
The criteria developed by Saaby et al.13 allow more
precise decisions but implementation is difficult in daily
clinical practice as the hospitals vary as do the wards.
Patients with T2MI had lower peak cardiac troponin
(cTn),13 and although all patients included in our study
had biomarker determinations, we were unable to com-
pare this due to multicenter participation of various
hospital types with different assays and different refer-
ence values. It could be postulated that by using sensitive
cTn assays more often, more patients would be classified
as having MI2. However, although high-sensitive tropo-
nin has been increasingly used, the percentage of patients
with MI2 did not constantly increase in our population.
It has been shown that patients with T2MI did not have
atherosclerotic plaque rupture compared with patients
with T1MI who seldom had normal coronary angiogra-
phies.5 Our unmatched and matched cohort of T1MI
patients – 0.3 and 0.2%, respectively – presented with no
significant coronary stenosis at angiography compared
with 7.2% of patients with T2MI. In the Swedish study,
42.4% of patients with T2MI had normal coronary
arteries or nonobstructive coronary artery disease
(<50% stenosis).14 The main difference between these
two cohort real-life studies is probably due to the differ-
ent definitions of angiographic findings.
A T2MI occurs secondary to an ischemic imbalance
triggered by a condition such as spasm, arrhythmia,
anemia, hypertension or hypotension.15 In the clinical
setting, it is sometimes difficult to estimate the true
impact of any of these conditions. For example, it is
often not known whether ischemia precipitated the atrial
fibrillation or atrial fibrillation precipitated the ischemia.5
Even severe vasospasm is difficult to diagnose and treat,16
and distinguishing T1MI from T2MI, particularly in the
perioperative period after noncardiac surgery, is often
challenging.5 In a retrospective review of the medical
records of 107 patients with T2MI, the most common
causes were sepsis, anemia and atrial fibrillation.17 In this
study, the presence of identifiable provoking factors was
known for 63% patients with T2MI, and the most fre-
quent clinical presentations thought to be causal were
anemia, atrial fibrillation and perioperative status. We
have already showed that patients suffering AMI when
already in hospital for other reasons had a worse prognosis
than those with outpatient-onset AMI.8
As yet, there is no consensus on the treatment of patients
with a presumptive diagnosis of T2MI. Given the phy-
siopathology, aggressive anticoagulation, platelet inhi-
bition and early PCI could potentially be harmful, and
the first line of treatment should often be limited to the
underlying conditions.15 In this study, most T2MI
patients with coronary angiography underwent PCI. It
could be assumed that the operator must have considered
that he/she was dealing with stable coronary disease with
an additional trigger that led to MI. Our data confirm that
many Swiss hospitals appear to have adopted this
approach, as the choice of treatment is determined by
the type of MI. It should be recognized that ICD10 codes
are insufficient to clearly determine the MI types,2,18 and
this probably has major implications not only for health
service research but also for quality and performance
measures of hospitals using medical records.
Complications in hospital were similar for both T1MI and
T2MI patients except for acute renal failure, which
occurred more frequently in patients with T2MI. In-
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Fig. 2
Cardiogenic shock
Reinfarction
Cerebrovascular event
Acute renal failure
Bleeding
In-hospital mortality
MACCE
0.2 0.5 1 2 4
OR (95% Cl)
0.90 (0.62–1.32)
0.68 (0.28–1.68)
1.24 (0.63–2.47)
1.85 (1.30–2.64)
1.05 (0.75–1.47)
1.15 (0.88–1.50)
1.11 (0.87–1.42)
Odds ratios with 95% confidence intervals of complications and
outcomes in a crude cohort of patients with myocardial infarction type 2
vs. patients with myocardial infarction type 1.
Fig. 3
Cardiogenic shock
Reinfarction
Cerebrovascular event
Acute renal failure
Bleeding
In-hospital mortality
MACCE
0.2 0.5 1 2 4
OR (95% Cl)
0.93 (0.56–1.56)
0.62 (0.20–1.91)
1.00 (0.40–2.53)
1.25 (0.76–2.05)
1.28 (0.79–2.08)
1.04 (0.72–1.49)
1.01 (0.73–1.42)
Odds ratios with 95% confidence intervals of complications and
outcomes in a propensity matched cohort of patients with myocardial
infarction type 2 vs. patients with myocardial infarction type 1.
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hospital mortality was not significantly different between
T1MI and T2MI patients (unmatched and matched).
Unadjusted 1-year mortality was higher in T2MI
patients, but adjusted mortality was similar to that of
T1MI patients, suggesting that baseline differences
rather than type of MI were the main drivers of longer
term mortality. Similarly, crude 1-year all-cause mortality
in the Swedish study (used merging with the National
Population Registry) was much higher (24.7% for T2MI
vs. 13.5% for T1MI), but the difference also disappeared
after adjustment for baseline characteristics.14 In con-
trast, the results from one single-center study in
Denmark reported mortality of 119 patients with
T2MI as high as 50% after 2 years.19 This high mortality
could be at least partially explained by older age (75
years) and the higher rate of comorbidities (heart failure
22%, prior stroke 20%, chronic obstructive pulmonary
disease 26% and diabetes 24%) of these unselected
hospital cohort patients.
Limitations
Our study should be considered under some clear limita-
tions. First, this is an observational study, and the classi-
fication of MI type was based solely on the treating
physician’s judgment, which was without external vali-
dation and could often have been an educated guess.
Second, in the data collection, there was not complete
information on the possible precipitating causes of type 2
MI. Furthermore, the rate of T2MI (e.g. perioperative
MI) could be underestimated due to treatment of these
patients in clinical departments other than cardiology,
and therefore they were not enrolled in AMIS Plus.
However, there are no clear diagnostic criteria for
T2MI, and we believe that the large number of patients
included in this cohort study should contribute to
improve our understanding of the use of the MI type
classification and set the stage for better defining the
treatment of patients with T2MI.
Finally, the number of patients with 1-year follow-up
data is relatively small and may not be fully representa-
tive of the entire cohort. However, there are only few data
in the literature on long-term outcomes of patients with
T2MI. Our data may therefore contribute to a better
understanding and may serve as an incentive for
further studies.
Conclusion
Our data document significant differences in clinical
presentation, baseline characteristics, treatment and both
early and late outcomes between patients with T2MI and
T1MI in routine clinical practice. Patients with T2MI
presented less frequently with typical symptoms, but
often with atrial fibrillation and anemia, and were less
frequently aggressively treated with anticoagulants, pla-
telet inhibition or PCI. After correcting for baseline
characteristics, complications and mortality in hospital
and 1 year after discharge were similar for patients with
T1MI and T2MI. Patients with type 2MI require further
investigation to better define it and achieve a consensus
on optimal therapeutic approaches.
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